Form 4 for TVTX Travere Therapeutics, Inc.
Accepted 2026-04-23 16:05:06 ET · period of report 2026-04-22 · accession 0001698262-26-000003 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| T | 2026-04-23 16:05 | 2026-04-22 | TVTX | ROTE WILLIAM E. | Chief Research Off | S - Sale | $39.09 | -9,100 | 114.0K | -7% | -$355.7K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2026-04-22 | S | D | 9,100 | $39.09 | 113,987 | D | — | — | (F1) This sale was made pursuant to a written plan adopted on May 29, 2025, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and includes the sale of shares to cover the tax obligation that occurred upon the vesting of performance restricted stock units. |